{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:38:29Z","timestamp":1768034309084,"version":"3.49.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.dsx.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T21:46:01Z","timestamp":1488836761000},"page":"S295-S305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S1","title":["The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents"],"prefix":"10.1016","volume":"11","author":[{"given":"Luca","family":"Di Lullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"De Pascalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.dsx.2017.03.005_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000321857","article-title":"A quantitative approach to drug dosing in chronic kidney disease","volume":"31","author":"Olyaei","year":"2011","journal-title":"Blood Purif"},{"key":"10.1016\/j.dsx.2017.03.005_bib0010","first-page":"229","article-title":"Addressing the global burden of chronic kidney disease through clinical and translational research","volume":"125","author":"Ojo","year":"2014","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.dsx.2017.03.005_bib0015","doi-asserted-by":"crossref","first-page":"132405","DOI":"10.4061\/2011\/132405","article-title":"Hypertension in chronic kidney disease: navigating the evidence","volume":"2011","author":"Tedla","year":"2011","journal-title":"Int J Hypertens"},{"issue":"6","key":"10.1016\/j.dsx.2017.03.005_bib0020","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s11255-013-0407-1","article-title":"The risk of atherosclerosis in patients with chronic kidney disease","volume":"45","author":"Olechnowicz-Tietz","year":"2013","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0025","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2014.01.065","article-title":"Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and\/or diabetic patients. A meta-regression analysis of 32 randomized trials","volume":"172","author":"Savarese","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0035","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and manage- ment of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes(KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1016\/j.dsx.2017.03.005_bib0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.07891109","article-title":"Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes","volume":"5","author":"Plantinga","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.dsx.2017.03.005_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2296-11-49","article-title":"Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores","volume":"11","author":"Hippisley-Cox","year":"2010","journal-title":"BMC Fam Pract"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","article-title":"Microvascular complications of diabetes","volume":"26","author":"Fowler","year":"2008","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.dsx.2017.03.005_bib0055","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"issue":"Suppl. 2","key":"10.1016\/j.dsx.2017.03.005_bib0060","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.2337\/dcS13-2009","article-title":"Genetic screening for the risk of type 2 diabetes: worthless or valuable?","volume":"36","author":"Lyssenko","year":"2013","journal-title":"Diabetes Care"},{"issue":"9131","key":"10.1016\/j.dsx.2017.03.005_bib0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2017.03.005_bib0070","series-title":"Glucophage (metformin) Summary of Product Characteristics","author":"Merck Serono","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0075","series-title":"Minodiab (glipizide) Summary of Product Characteristics","author":"Pfizer Limited","year":"2014"},{"key":"10.1016\/j.dsx.2017.03.005_bib0080","series-title":"Glibenclamide Summary of Product Characteristics","author":"Wockhardt UK Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0085","series-title":"Gliclazide Summary of Product Characteristics","author":"Wockhardt UK Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0090","series-title":"Glimepiride Summary of Product Characteristics","author":"Accord Healthcare Limited","year":"2014"},{"key":"10.1016\/j.dsx.2017.03.005_bib0095","series-title":"Prandin (repaglinide) Summary of Product Characteristics","author":"Novo Nordisk Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0100","series-title":"Humulin I (isophane insulin) Summary of Product Characteristics","author":"Eli Lilly and Company Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0105","series-title":"Lantus (insulin glargine) Summary of Product Characteristics","author":"Sanofi-aventis","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0110","series-title":"Levemir (insulin detemir) Summary of Product Characteristics","author":"Novo Nordisk Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0115","series-title":"Tresiba (insulin degludec) Summary of Product Characteristics","author":"Novo Nordisk Limited","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0120","series-title":"Humalog (insulin lispro) Summary of Product Characteristics","author":"Eli Lilly and Company Limited","year":"2014"},{"key":"10.1016\/j.dsx.2017.03.005_bib0125","series-title":"Apidra (insulin glulisine) Summary of Product Characteristics","author":"Sanofi","year":"2013"},{"key":"10.1016\/j.dsx.2017.03.005_bib0130","series-title":"NovoMix (insulin aspart) Summary of Product Characteristics","author":"Novo Nordisk Limited","year":"2014"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2337\/diacare.21.10.1659","article-title":"Lactic acidosis rates in type 2 diabetes","volume":"21","author":"Brown","year":"1998","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.dsx.2017.03.005_bib0145","series-title":"The manage- ment of type 2 diabetes (CG87)","author":"National Institute for Health and Care Excellence (NICE)","year":"2017"},{"issue":"24","key":"10.1016\/j.dsx.2017.03.005_bib0150","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.dsx.2017.03.005_bib0155","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dsx.2017.03.005_bib0160","series-title":"Actos (pioglitazone) Summary of Product Characteristics","author":"Takeda","year":"2014"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0165","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00002018-200831100-00003","article-title":"Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England","volume":"31","author":"Kasliwal","year":"2008","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.dsx.2017.03.005_bib0170","first-page":"490","article-title":"Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents","volume":"34","author":"Shaya","year":"2009","journal-title":"Pharm Ther"},{"key":"10.1016\/j.dsx.2017.03.005_bib0175","series-title":"Acarbose Summary of Product Characteristics","author":"Actavis UK Ltd","year":"2013"},{"key":"10.1016\/j.dsx.2017.03.005_bib0180","series-title":"Symlin (pramlintide acetate) Prescribing Information","author":"AstraZeneca AB","year":"2014"},{"key":"10.1016\/j.dsx.2017.03.005_bib0185","series-title":"Cycloset (bromocriptine) Prescribing Information","author":"VeroScience","year":"2016"},{"issue":"5","key":"10.1016\/j.dsx.2017.03.005_bib0190","first-page":"608","article-title":"Insulin degradation: progress and potential","volume":"19","author":"Duckworth","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.dsx.2017.03.005_bib0195","series-title":"Toujeo (insulin glargine) Summary of Product Characteristics","author":"Sanofi","year":"2015"},{"key":"10.1016\/j.dsx.2017.03.005_bib0200","first-page":"A259","article-title":"Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment","volume":"45","author":"Jacobsen","year":"2002","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200767030-00006","article-title":"Insulin lispro: a review of its use in the management of diabetes mellitus","volume":"67","author":"Simpson","year":"2007","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?","volume":"10","author":"Muskiet","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0215","doi-asserted-by":"crossref","first-page":"e111543","DOI":"10.1371\/journal.pone.0111543","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000357680","article-title":"Novel hypoglycaemic agents: considerations in patients with chronic kidney disease","volume":"126","author":"Game","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.dsx.2017.03.005_bib0230","doi-asserted-by":"crossref","first-page":"e005752","DOI":"10.1136\/bmjopen-2014-005752","article-title":"Safety and effectiveness of dipepti- dyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis","volume":"4","author":"Tricco","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0235","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0245","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0250","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jdi.12142","article-title":"Sitagliptin improves albu- minuria in patients with type 2 diabetes mellitus","volume":"5","author":"Mori","year":"2014","journal-title":"J Diabetes Investig"},{"issue":"7","key":"10.1016\/j.dsx.2017.03.005_bib0255","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2337\/dc06-2545","article-title":"Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor","volume":"30","author":"Bergman","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2017.03.005_bib0260","series-title":"Januvia (sitagliptin) Summary of Product Characteristics","author":"Merck Sharp and Dohme Limited","year":"2015"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0265","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/dmd.108.023010","article-title":"Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans","volume":"37","author":"He","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dsx.2017.03.005_bib0270","first-page":"P687","article-title":"DPP-4 inhibitor vildagliptin reduces urinary albumin excretion in type 2 diabetic patients with microalbuminuria","volume":"29","author":"Watanabe","year":"2012","journal-title":"Endocr Abstr"},{"issue":"Suppl. 1","key":"10.1016\/j.dsx.2017.03.005_bib0275","first-page":"S113","article-title":"The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86)","volume":"81","author":"He","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dsx.2017.03.005_bib0280","doi-asserted-by":"crossref","first-page":"693","DOI":"10.5414\/CP201885","article-title":"Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment","volume":"51","author":"He","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.dsx.2017.03.005_bib0285","series-title":"Galvus (vildagliptin) Summary of Product Characteristics","author":"Novartis Pharmaceuticals UK Ltd","year":"2016"},{"issue":"4","key":"10.1016\/j.dsx.2017.03.005_bib0290","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/11584350-000000000-00000","article-title":"Influence of renal or hepatic impair- ment on the pharmacokinetics of saxagliptin","volume":"50","author":"Boulton","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dsx.2017.03.005_bib0295","series-title":"Onglyza (saxagliptin) Summary of Product Characteristics","author":"AstraZeneca UK Limited","year":"2015"},{"issue":"11","key":"10.1016\/j.dsx.2017.03.005_bib0300","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2017.03.005_bib0305","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0310","first-page":"186","article-title":"Alogliptin (nesina) for adults with type-2 diabetes","volume":"39","author":"Dineen","year":"2014","journal-title":"Pharm Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.dsx.2017.03.005_bib0315","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1326.2011.01457.x","article-title":"The future of incretin-based therapy: novel avenues\u2013novel targets","volume":"13","author":"Ahren","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.dsx.2017.03.005_bib0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3810\/pgm.2014.10.2821","article-title":"Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes","volume":"126","author":"Kuritzky","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dsx.2017.03.005_bib0325","doi-asserted-by":"crossref","first-page":"g2366","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancrea- titis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.dsx.2017.03.005_bib0330","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.dsx.2017.03.005_bib0335","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000337929","article-title":"Exenatide reduces urinary transform- ing growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria","volume":"35","author":"Zhang","year":"2012","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0340","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1620\/tjem.231.57","article-title":"The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephro- pathy in type 2 diabetic patients","volume":"231","author":"Imamura","year":"2013","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"10.1016\/j.dsx.2017.03.005_bib0345","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0350","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dsx.2017.03.005_bib0355","series-title":"Byetta (exenatide) Summary of Product Characteristics","author":"AstraZeneca UK Limited","year":"2016"},{"key":"10.1016\/j.dsx.2017.03.005_bib0360","series-title":"Bydureon (exenatide) Summary of Product Characteristics","author":"AstraZeneca UK Limited","year":"2016"},{"key":"10.1016\/j.dsx.2017.03.005_bib0365","series-title":"Lyxumia (lixisenatide) Summary of Product Characteristics","author":"Sanofi-aventis","year":"2014"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0370","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-014-0519-0","article-title":"One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study","volume":"50","author":"Zavattaro","year":"2015","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.dsx.2017.03.005_bib0380","first-page":"S349","article-title":"Pharmacokinetics of once weekly dulaglutide in special populations","volume":"57","author":"Loghin","year":"2014","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.dsx.2017.03.005_bib0385","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their effi y and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3810\/pgm.2014.05.2754","article-title":"Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide","volume":"126","author":"Young","year":"2014","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/03007990802710422","article-title":"From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus","volume":"25","author":"Bays","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.dsx.2017.03.005_bib0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.1016\/j.dsx.2017.03.005_bib0405","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.dsx.2017.03.005_bib0410","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.dsx.2017.03.005_bib0415","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treat- ment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0420","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bcp.12056","article-title":"The influence of kidney function on dapaglifl exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus","volume":"76","author":"Kasichayanula","year":"2013","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"10.1016\/j.dsx.2017.03.005_bib0425","first-page":"656","article-title":"Canagliflozin (Invokana), a novel oral agent for type-2 diabetes","volume":"38","author":"Sarnoski-Brocavich","year":"2013","journal-title":"Pharm Ther"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0430","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.dsx.2017.03.005_bib0435","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40261-014-0226-x","article-title":"Pharmacokinetic and pharma- codynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment","volume":"34","author":"Inagaki","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0440","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.dsx.2017.03.005_bib0445","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.dsx.2017.03.005_bib0450","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"EMPA-REG Renal Trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.dsx.2017.03.005_bib0455","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2017.03.005_bib0460","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibi- tors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.dsx.2017.03.005_bib0465","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402117300644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402117300644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T08:14:07Z","timestamp":1658736847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402117300644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":93,"alternative-id":["S1871402117300644"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2017.03.005","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}